Larvol announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the MAPS Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.
SAN FRANCISCO–(BUSINESS WIRE) – Larvol, a San Francisco-based pharma SaaS (Software as a Service) company, announced the launch of Omni, their newest Medical Communications and Competitive Intelligence tool at the Medical Affairs Professional Society Annual Conference in New Orleans, LA. The Omni platform, available on both desktop and mobile devices, offers users the ability to track developments related to Key Opinion Leaders, including conferences, social media, and clinical trials in real time.
“We were emboldened by the feedback we received from our customers to develop a dynamic platform that can be widely adopted by Med Comm and Med Affairs teams as well as CI pros who have been relying on our solutions in the pharma industry for more than a decade,” said CEO Dr. Aviva Fridman. “I am excited to get Omni into the hands of customers who will benefit from instant access to their market and KOL data.”
Omni enables users to choose their target KOLs and access their activity instantly via their desktop or mobile device. Features include:
Larvol provides SaaS solutions that support competitive intelligence, business intelligence, and medical communications departments in the pharmaceutical and biotech industry. Their products include secondary competitive intelligence reports, KOL tracking, and conference planning solutions. Larvol curates pharmaceutical and biotech competitive intelligence using a proven combination of broad therapeutic-area expertise and technological innovation to keep their customers at the forefront of the industry. The Larvol team consists of MDs and PhDs who curate data from over 25,000 sources and distill the most relevant findings into concise reports that provide real-time insights and time-saving analysis.
For more information about Larvol or sales inquiries, please contact us at firstname.lastname@example.org. New users can register at www.larvolomni.com.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.
Well-established biomarkers in breast cancer today include BRCA1/BRCA2, estrogen and progesterone receptors as well as p53, which is the most studied biomarker in breast cancer. Let’s look at some of the biomarkers that are emerging in this space.